Using Novel Immune Modulatory Treatment Options in Head and Neck Cancer: On-Demand Simulcast

Did you miss the symposium in Scottsdale? Review this on-demand simulcast of the live event as our distinguished faculty, Maura L. Gillison, MD, PhD; Barbara Ann Burtness, MD; and Everett Vokes, MD review practical guidance in integrating immunotherapy agents into therapeutic strategies to improve outcomes for patients with HNSCC.
Barbara Ann Burtness, MD
Maura L. Gillison, MD, PhD
Everett Vokes, MD
Released: March 9, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the role of the immune system and immune escape in HNSCC, along with the mechanisms of action of different immune modulatory agents
  • Plan therapeutic strategies for patients with recurrent metastatic HNSCC that has progressed on or after platinum-containing chemotherapy
  • Discuss the latest science and clinical trial results of immunotherapy agents or combinations being investigated as first-line treatment of locoregionally advanced or metastatic HNSCC
  • Identify appropriate candidates for clinical trials of IDO inhibitors and other emerging immune modulatory agents alone or in combination for HNSCC
  • Identify and manage immune-related toxicities associated with immune checkpoint inhibitors in patients with HNSCC

Information on this Educational Activity


Barbara Ann Burtness, MD

Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Barbara Ann Burtness, MD, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, IDDI, and Merck.

Maura L. Gillison, MD, PhD

Division of Cancer Medicine
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Maura L. Gillison, MD, PhD, has disclosed that she has received consulting fees from Aspyrian Therapeutics, Inc., Bristol-Myers Squibb, EMD Serono, and Merck.

Everett Vokes, MD

John E. Ultmann Professor
Department of Medicine
University of Chicago Medical and Biologic Sciences
Chicago, Illinois

Everett Vokes, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Ariad, AstraZeneca, Bayer, Biolumina, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genentech, Leidos, Merck, Novartis, Regeneron, Takeda, and VentiRx and funds for research support from AbbVie and Bristol-Myers Squibb.


Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Krista Marcello

Managing Editor

Krista Marcello, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Target Audience

This activity is intended for medical oncologists, radiation oncologists, surgical oncologists, and head and neck surgeons who care for patients with head and neck squamous cell carcinoma.


The goal of this activity is to improve participants' competence in incorporating immunotherapies in the treatment of patients with head and neck squamous cell carcinoma.

Program Medium

This program has been made available online.

Related Content

Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: July 10, 2018 Expiration: July 9, 2019

Expert commentary from Manish A. Shah, MD, on recent developments in targeting cancer stem cells in gastrointestinal cancers, including data from ASCO 2018.

Manish A. Shah, MD Released: June 28, 2018

Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.

Daniel P. Petrylak, MD Released: June 20, 2018

Results from KEYNOTE-042 trial of first-line pembrolizumab vs standard chemotherapy in advanced NSCLC with PD-L1 TPS ≥ 1% from ASCO 2018 reported by Clinical Care Options (CCO).

Released: June 13, 2018


Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by an educational grant from
Bristol-Myers Squibb

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?